BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 22361471)

  • 1. Anti-human leukocyte antigen immunization after early allograft nephrectomy.
    Del Bello A; Congy N; Sallusto F; Cardeau-Desangles I; Fort M; Esposito L; Guitard J; Cointault O; Lavayssière L; Nogier MB; Game X; Blancher A; Rostaing L; Kamar N
    Transplantation; 2012 May; 93(9):936-41. PubMed ID: 22361471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation.
    Caro-Oleas JL; González-Escribano MF; González-Roncero FM; Acevedo-Calado MJ; Cabello-Chaves V; Gentil-Govantes MÁ; Núñez-Roldán A
    Nephrol Dial Transplant; 2012 Mar; 27(3):1231-8. PubMed ID: 21810767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure.
    Cai J; Terasaki PI; Anderson N; Lachmann N; Schönemann C
    Transplantation; 2009 Jul; 88(2):226-30. PubMed ID: 19623018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts.
    Lachmann N; Terasaki PI; Budde K; Liefeldt L; Kahl A; Reinke P; Pratschke J; Rudolph B; Schmidt D; Salama A; Schönemann C
    Transplantation; 2009 May; 87(10):1505-13. PubMed ID: 19461487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretransplant donor-specific HLA antibodies detected by single antigen bead flow cytometry: risk factors and outcomes after kidney transplantation.
    Kanter Berga J; Sancho Calabuig A; Gavela Martinez E; Puig Alcaraz N; Beltran Catalan S; Avila Bernabeu A; Crespo Albiach J; Montoro JA; Pallardo Mateu LM
    Transplant Proc; 2012 Nov; 44(9):2529-31. PubMed ID: 23146444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
    Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
    Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo donor specific antibodies and patient outcomes in renal transplantation.
    DeVos JM; Patel SJ; Burns KM; Dilioglou S; Gaber LW; Knight RJ; Gaber AO; Land GA
    Clin Transpl; 2011; ():351-8. PubMed ID: 22755430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
    Li X; Ishida H; Yamaguchi Y; Tanabe K
    Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
    Ho EK; Vlad G; Vasilescu ER; de la Torre L; Colovai AI; Burke E; Deng M; Schwartz J; Marboe C; Mancini D; Opelz G; Suciu-Foca N
    Hum Immunol; 2011 Jan; 72(1):5-10. PubMed ID: 20971146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-HLA antibodies and kidney allograft outcomes in recipients with donor bone marrow cell infusion.
    Solgi G; Pourmand G; Mehrsai A; Taherimahmoudi M; Nicknam MH; Ebrahimi Rad MR; Seraji A; Asadpoor A; Ansaripor B; Nikbin B; Amirzargar A
    Iran J Immunol; 2010 Mar; 7(1):18-29. PubMed ID: 20371916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
    Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes.
    Freitas MC; Rebellato LM; Ozawa M; Nguyen A; Sasaki N; Everly M; Briley KP; Haisch CE; Bolin P; Parker K; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 May; 95(9):1113-9. PubMed ID: 23514959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation.
    Musat AI; Pigott CM; Ellis TM; Agni RM; Leverson GE; Powell AJ; Richards KR; D'Alessandro AM; Lucey MR
    Liver Transpl; 2013 Oct; 19(10):1132-41. PubMed ID: 23873778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
    Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
    Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics and epitope specificity of anti-human leukocyte antibodies following renal allograft nephrectomy.
    Lachmann N; Schönemann C; El-Awar N; Everly M; Budde K; Terasaki PI; Waiser J
    Nephrol Dial Transplant; 2016 Aug; 31(8):1351-9. PubMed ID: 27190369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abrogation of anti-HLA antibodies via proteasome inhibition.
    Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
    Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor-specific HLA antibodies: risk factors and outcomes after kidney transplantation.
    Kanter Berga J; Pallardo Mateu LM; Beltran Catalan S; Puig Alcaraz N; Sancho Calabuig A; Gavela Martinez E; Avila Bernabeu A; Crespo Albiach J
    Transplant Proc; 2011; 43(6):2154-6. PubMed ID: 21839219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation.
    Caro-Oleas JL; González-Escribano MF; Gentil-Govantes MÁ; Acevedo MJ; González-Roncero FM; Blanco GB; Núñez-Roldán A
    Transplantation; 2012 Aug; 94(4):338-44. PubMed ID: 22814330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.